The role of hormone replacement therapy in the prevention of Alzheimer disease

Archives of Internal Medicine

Volumn 162, Issue 17, 2002, Pages 1934-1942

  Fillit, Howard M ^a  

^a Alzheimers Drug Discovery Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; ESTROGEN;

ALZHEIMER DISEASE; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; COGNITION; DEMENTIA; DISEASE COURSE; ESTROGEN THERAPY; FEMALE; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; LEARNING; MEMORY; NEUROPROTECTION; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SEX HORMONE DETERMINATION;

ALZHEIMER DISEASE; BRAIN; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; PREVALENCE; SEX FACTORS; UNITED STATES;

EID: 0037163491     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.17.1934     Document Type: Review

References (125)

1. Evans DA, Scherr PA, Cook NR, et al. Estimated prevalence of Alzheimer's disease in the United States. Milbank O. 1990;68:267-289.
2. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-1342.
3. Molsa PK, Marttila RJ, Rinne UK. Epidemiology of dementia in a Finnish population. Acta Neurol Scand. 1982;65:541-552.
4. Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: A meta-analysis. Arch Gen Psychiatry. 1998;55:809-815.
5. Fillit H, Luine V. The neurobiology of gonadal hormones and cognitive decline in late life. Maturitas. 1997;26:159-164.
6. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol. 1994;140:256-261.
7. Woolley CS, Gould E, Frankfurt M, McEwen BS. Naturally occurring fluctuation in dendritic spine density on adult hippocampal pyramidal neurons. J Neurosci. 1990;10:4035-4039.
8. Woolley CS, McEwen BS. Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat. J Comp Neurol. 1993;336:293-306.
9. Murphy DD, Segal M. Regulation of dendritic spine density in cultured rat hippocampal neurons by steroid hormones. J Neurosci. 1996;16: 4059-4068.
10. Singer CA, Rogers KL, Strickland TM, Dorsa DM. Estrogen protects primary cortical neurons from glutamate toxicity. Neurosci Lett. 1996;212:13-16.
11. Gibbs RB, Aggarwal P. Estrogen and basal forebrain cholinergic neurons: implications for brain aging and Alzheimer's disease-related cognitive decline. Horm Behav. 1998;34:98-111.
12. Inestrosa NC, Marzolo MP, Bonnefont AB. Cellular and molecular basis of estrogen's neuro-protection: potential relevance for Alzheimer's disease. Mol Neurobiol. 1998;17:73-86.
13. Murphy DD, Cole NB, Segal M. Brain-derived neurotrophic factor mediates estradiol-induced dendritic spine formation in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95:11412-11417.
14. Singh M, Meyer EM, Millard WJ, Simpkins JW. Ovarian steroid deprivation results in reversible learning impairment and compromised cholinergic function in Sprague-Dawley rats. Brain Res. 1994;644:305-312.
15. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol. 1994;83:979-983.
16. Robinson D, Friedman L, Marcus R, Tinklenberg J, Yesavage J. Estrogen replacement therapy and memory in older women. J Am Geriatr Soc. 1994;42:919-922.
17. Schmidt R, Fazekas F, Reinhart B, et al. Estrogen replacement therapy in older women: a neuropsychological and brain MRI study. J Am Geriatr Soc. 1996;44:1307-1313.
18. Rice MM, Graves AB, McCurry SM, Larson EB. Estrogen replacement therapy and cognitive function in postmenopausal women without dementia. Am J Med. 1997; 103(suppl 3A):26S-35S.
19. Shaywitz SE, Shaywitz BA, Pugh KR, et al. Effect of estrogen on brain activation patterns in post-menopausal women during working memory tasks. JAMA. 1999;281:1197-1202.
20. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA. 1993;269:2637-2641.
21. Resnick SM, Metter EJ, Zonderman AB. Estrogen replacement therapy and longitudinal decline in visual memory: a possible protective effect? Neurology. 1997;49:1491-1497.
22. Jacobs DM, Tang M-X, Stern Y, et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology. 1998;50: 368-373.
23. Matthews K, Cauley J, Yaffe K, Zmuda JM. Estrogen replacement therapy and cognitive decline in older community women. J Am Geriatr Soc. 1999;47:518-523.
24. Steffens DC, Norton MC, Plassman BL, et al. Enhanced cognitive performance with estrogen use in nondemented community-dwelling older women. J Am Geriatr Soc. 1999;47:1171-1175.
25. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med. 1996;156:2213-2217.
26. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 1996;348: 429-432.
27. Baldereschi M, Di Carlo A, Lepore V, et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology. 1998;50:996-1002.
28. Waring SC, Rocca WA, Petersen RC, O'Brien PC, Tangalos EG, Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: A population-based study. Neurology. 1999;52: 965-970.
29. Seshadri S, Zornberg GL, Derby LE, Myers MW, Jick H, Drachman DA. Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease. Arch Neurol. 2001;58:435-440.
30. Fillit H, Weinreb H, Cholst I, et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuro-endocrinology. 1986;11:337-345.
31. Honjo H, Ogino Y, Naitoh K, et al. In vivo effects by estrone sulfate on the central nervous systemsenile dementia (Alzheimer's type). J Steroid Biochem. 1989;34:521-525.
32. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr J. 1994;41:361-371.
33. Asthana S, Craft S, Baker LD, et al. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: Results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology. 1999;24:657-677.
34. Mulnard RA, Cotman CW, Kawas CW, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. JAMA. 2000;283:1007-1015.
35. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: A meta-analysis. Neuroscience. 2000;101:485-512.
36. Panidis DK, Matalliotakis IM, Rousso DH, Kourtis Al, Koumantakis EE. The role of estrogen replacement therapy in Alzheimer's disease. Eur J Obstet Gynecol Reprod Biol. 2001; 95:86-91.
37. Petersen RC, Smith GE, Ivnik RJ, et al Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA. 1995;273:1274-1278.
38. Yaffe K, Haan M, Byers A, Tangen C, Kuller L. Estrogen use, APOE, and cognitive decline: Evidence of gene-environment interaction. Neurology. 2000;54:1949-1954.
39. Naslund J, Thyberg J, Tjernberg LO, etal. Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain. Neuron. 1995;15: 219-228.
40. Schmechel D, Saunders AM, Trittmatter WJ, et al. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:9649-9653.
41. De Lacoste MC, White CL. The role of cortical connectivity in Alzheimer's disease pathogenesis: A review and model system. Neurobiol Aging. 1993;14:1-16.
42. Delacourte A, David JP, Sergeant N, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology. 1999;52:1158-1165.
43. Yilmazer-Hanke DM, Hanke J. Progression of Alzheimer-related neuritic plaque pathology in the entorhinal region, perirhinal cortex and hippocampal formation. Dement Geriatr Cogn Disord. 1999;10:70-76.
44. Price DL. New perspectives on Alzheimer's disease. Annu Rev Neurosci. 1986;9:489-512.
45. Jellinger K. Morphology of Alzheimer's disease and related disorders. In: Maurer K, Riederer P, Beckman H, eds. Alzheimer's Disease: Epidemiology, Neuropathology, Neurochemistry, and Clinics. New York, NY: Chapman & Hall; 1990: 61-77.
46. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83:4913-4917.
47. Raskind MA, Peskind ER. Alzheimer's disease and related disorders. Med Clin North Am. 2001;85: 803-817.
48. Selkoe DJ. Amyloid β-protein and the genetics of Alzheimer's disease. J Biol Chem. 1996;271: 18295-18298.
49. Behl C, Skutella T, Lezoualc'h F, et al. Neuroprotection against oxidative stress by estrogens: Structure-activity relationship. Mol Pharmacol. 1997;51:535-541.
50. Brinton RD, Chen S, Montoya M, Hsieh D, Minaya J. The estrogen replacement therapy of the Women's Health Initiative promotes the cellular mechanisms of memory and neuronal survival in neurons vulnerable to Alzheimer's disease. Maturitas. 2000;34(suppl 2):S35-S52.
51. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science. 1982;215:1237-1239.
52. Olton DS. Dementia: Animal models of the cognitive impairments following damage to the basal forebrain cholinergic system. Brain Res Bull. 1990;25:499-502.
53. McEntee WJ, Crook TH. Cholinergic function in the aged brain: Implications for treatment of memory impairments associated with aging. Behav Pharmacol. 1992;3:327-336.
54. Sims NR, Bowen DM, Smith CCT, et al. Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease. Lancet. 1980;1:333-336.
55. Fibiger HC. Cholinergic mechanisms in learning, memory and dementia: A review of recent evidence. Trends Neurosci. 1991;14:220-223.
56. Muir JL. Acetylcholine, aging, and Alzheimer's disease. Pharmacol Biochem Behav. 1997;56: 687-696.
57. Luine VN. Estradiol increases choline acetyl-transferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol. 1985;89:484-490.
58. Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE. Estrogen regulates metabolism of Alzheimer amyloid-β precursor protein. J Biol Chem. 1994;269:13065-13068.
59. Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosteroid exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurons. J Neurochem. 1996;66:1836-1844.
60. Gridley KE, Green PS, Simpkins JW. Low concentrations of estradiol reduce β-amyloid (25-35)-induced toxicity, lipid peroxidation and glucose utilization in human SK-N-SH neuroblastoma cells. Brain Res 1997;778:158-165.
61. Keller JN, Germeyer A, Begley JG, Mattson MP. 17β-Estradiol attenuates oxidative impairment of synaptic Na+/K+-ATPase activity, glucose transport, and glutamate transport induced by amyloid β-peptide and iron. J Neurosci Res. 1997;50: 522-530.
62. Bonnefont AB, Munoz FJ, Inestrosa NC. Estrogen protects neuronal cells from the cytotoxicity induced by acetylcholinesterase-amyloid complexes. FEBS Lett. 1998;441:220-224.
63. Xu H, Gouras GK, Greenfield JP, et al. Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides. Nat Med. 1998;4:447-451.
64. Thomas T, Rhodin J. Vascular actions of estrogen and Alzheimer's disease. Ann N Y Acad Sci. April 2000:501-509.
65. Vincent B, Smith JD. Effect of estradiol on neuronal Swedish-mutated β-amyloid precursor protein metabolism: Reversal by astrocytic cells. Biochem Biophys Res Commun. 2000;271:82-85.
66. Brinton RD. 17β-estradiol induction of filopodial growth in cultured hippocampal neurons within minutes of exposure. Mol Cell Neurosci. 1993;4:36-46.
67. Brinton RD, Tran J, Proffitt P, Montoya M. 17β-estradiol enhances the outgrowth and survival of neocortical neurons in culture. Neurochem Res. 1997;22:1339-1351.
68. Gibbs RB, Hashash A, Johnson DA. Effects of estrogen on potassium-stimulated acetylcholine release in the hippocampus and overlying cortex of adult rats. Brain Res. 1997;749:143-146.
69. Fader AJ, Hendricson AW, Dohanich GP. Estrogen improves performance of reinforced T-maze alternation and prevents the amnestic effects of scopolamine administered systemically or intrahippocampally. Neurobiol Learn Mem. 1998;69:225-240.
70. Luine VN, Richards ST, Wu VY, Beck KD. Estradiol enhances learning and memory in a spatial memory task and affects levels of monoaminergic neurotransmitters. Horm Behav. 1998;34:149-162.
71. Gibbs RB. Estrogen replacement enhances acquisition of a spatial memory task and reduces deficits associated with hippocampal muscarinic receptor inhibition. Horm Behav. 1999;36: 222-233.
72. ,Newhouse PA, Hancur C, Kelton M, Naylor M. The effects of estrogen on anti-cholinergic-mediated cognitive impairment in post-menopausal women [abstract]. In: Programs and Abstracts From the 31st Annual Meeting of the Society for Neuroscience; November 10-15, 2001; San Diego, Calif [book on CD-ROM]. Washington, DC: Society for Neuroscience; 2001. Program 73.13.
73. Eberling JL, Wu C, Haan MN, Mungas D, Buonocore M, Jagust WJ. Gender differences in agerelated hippocampal atrophy: the role of estrogen [abstract]. In: Programs and Abstracts From the 31st Annual Meeting of the Society for Neuroscience; November 10-15, 2001, San Diego, Calif [book on CD-ROM]. Washington, DC: Society for Neuroscience; 2001. Program 550.2.
74. O'Malley CA, Hautamaki RD, Kelley M, Meyer EM. Effects of ovariectomy and estradiol benzoate on high affinity choline uptake, ACh synthesis, and release from rat cerebral cortical synaptosomes. Brain Res. 1987;403:389-392.
75. NGFR and ChAT expression in the medial septum and diagonal band of Broca. Exp NeuroL 1992;116:23-39.
76. Toran-Allerand CD, Miranda RC, Bentham WD, et al. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci U S A. 1992;89:4668-4672.
77. Miranda RC, Sohrabji F, Toran-Allerand CD. Presumptive estrogen target neurons express mRNAs for both the neurotrophins and neurotrophin receptors: a basis for potential developmental interactions of estrogen with the neuro-trophins. Mol Cell Neurosci. 1993;4:510-525.
78. Gibbs RB, Wu D, Hersh LB, Pfaff DW. Effects of estrogen replacement on the relative levels of choline acetyltransferase, trkA, and nerve growth factor messenger RNAs in the basal forebrain and hippocampal formation of adult rats. Exp Neurol. 1994;129:70-80.
79. McMillan PJ, Singer CA, Dorsa DM. The effects of ovariectomy and estrogen replacement on trkA and choline acetyltransferase mRNA expression in the basal forebrain of the adult female Sprague-Dawley rat. J Neurosci. 1996;16:1860-1865.
80. Gibbs RB. Effects of estrogen on basal forebrain cholinergic neurons vary as a function of dose and duration of treatment. Brain Res. 1997; 757:10-16.
81. Gibbs RB. Levels of trkA and BDNF mRNA, but not NGF mRNA, fluctuate across the estrous cycle and increase in response to acute hormone replacement. Brain Res. 1998;787:259-268.
82. Blurton-Jones MM, Roberts JA, Tuszynski MH. Estrogen receptor immunoreactivity in the adult primate brain: neuronal distribution and association with p75, trkA, and choline acetyltransferase. J Comp Neurol. 1999;405:529-542.
83. Gibbs RB. Effects of gonadal hormone replacement on measures of basal forebrain cholinergic function. Neuroscience. 2000;101:931-938.
84. Srivastava RAK, Srivastava N, Averna M, et al. Estrogen up-regulates apolipoprotein E (ApoE) gene expression by increasing ApoE mRNA in the translating pool via the estrogen receptor α-mediated pathway. J Biol Chem. 1997;272: 33360-33366.
85. Stone DJ, Rozovsky I, Morgan TE, Anderson CP, Finch CE. Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: implications for Alzheimer's disease. J Neurosci. 1998;18:3180-3185.
86. Teter B, Harris-White ME, Frautschy SA, Cole GM. Role of apolipoprotein E and estrogen in mossy fiber sprouting in hippocampal slice cultures. Neuroscience. 1999;91:1009-1016.
87. Mattson MP, Robinson N, Guo Q. Estrogens stabilize mitochondrial function and protect neural cells against the pro-apoptotic action of mutant presenilin-1. Neuroreport. 1997;8:3817-3821.
88. Bishop J, Simpkins JW. Estradiol enhances brain glucose uptake in ovariectomized rats. Brain Res Bull. 1995;36:315-320.
89. Ohkura T, Teshima Y, Isse K, et al. Estrogen increases cerebral and cerebellar blood flows in postmenopausal women. Menopause. 1995;2: 13-18.
90. Resnick SM, Maki PM, Golski S, Kraut MA, Zonderman AB. Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm Behav. 1998; 34:171-182
91. Maki PM, Resnick SM. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol Aging. 2000; 21:373-383.
92. Dubal DB, Wise PM. Neuroprotective effects of estradiol in middle-aged female rats. Endocrinology. 2001;142:43-48.
93. Österlund MK, Halldin C, Hurd YL. Effects of chronic 17β-estradiol treatment on the serotonin 5-HT(1A) receptor mRNA and binding levels in the rat brain. Synapse. 2000;35:39-44.
94. Bae YH, Hwang JY, Kim YH, Koh JY. Antioxidative neuroprotection by estrogens in mouse cortical cultures. J Korean Med Sci. 2000;15: 327-336.
95. Leanza G. Chronic elevation of amyloid precursor protein expression in the neocortex and hippocampus of rats with selective cholinergic lesions. Neurosci Lett. 1998;257:53-56.
96. Wong TP, Debeir T, Duff K, Cuello AC. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J Neurosci. 1999;19: 2706-2716.
97. Bronfman FC, Moechars D, Van Leuven F. Acetylcholinesterase-positive fiber deafferentation and cell shrinkage in the septohippocampal pathway of aged amyloid precursor protein London mutant transgenic mice. Neurobiol Dis. 2000;7:152-168.
98. Granholm AC: Oestrogen and nerve growth factor: neuroprotection and repair in Alzheimer's disease. Expert Opin Investig Drugs. 2000;9:685694.
99. Frankfurt M, Gould E, Woolley CS, McEwen BS. Gonadal steroids modify dendritic spine density in ventromedial hypothalamic neurons: a Golgi study in the adult rat. Neuroendocrinology. 1990;51:530-535.
100. Singh M, Meyer EM, Simpkins JW. The effect of ovariectomy and estradiol replacement on brainderived neurotrophic factor messenger ribonucleic acid expression in cortical and hippocampal brain regions of female SpragueDawley rats. Endocrinology. 1995;136:23202324.
101. Montoya DAC, Carrer HF. Estrogen facilitates induction of long term potentiation in the hippocampus of awake rats. Brain Res. 1997;778: 430-438.
102. Kar S, Seto D, Gaudreau P, Quirion R. β-Amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal slices. J Neurosci. 1996;16:1034-1040.
103. Toran-Allerand CD, Singh M, Sétáló G Jr. Novel mechanisms of estrogen action in the brain: new players in an old story. Front Neuroendocrinol. 1999;20:97-121.
104. Slooter AJ, Bronzova J, Witteman JC, Van Broeckhoven C, Hofman A, van Duijn CM. Estrogen use and early onset Alzheimer's disease: a population-based study. J Neurol Neurosurg Psychiatry. 1999;67:779-781.
105. Lendon CL, Lambert JC. Polymorphisms associated with risk for Alzheimer's disease modulate the estrogen induced expression of the apolipoprotein E gene: possible implications for hormone replacement therapy [abstract]. In: Programs and Abstracts From the 31st Annual Meeting of the Society for Neuroscience; November 10-15, 2001; San Diego, Calif [book on CD-ROM]. Washington, DC: Society for Neuroscience; 2001. Program 192.2.
106. Meda C, Vegeto E, Pollio G, et al. Oestrogen prevention of neural cell death correlates with decreased expression of mRNA for the proapoptotic protein nip-2. J Neuroendocrinol. 2000; 12:1051-1059.
107. Kalaria RN, Harik SI. Abnormalities of the glucose transporter at the blood-brain barrier and in brain in Alzheimer's disease. Prog Clin Biol Res. 1989;317:415-421.
108. Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T. Alzheimer's disease: a study of epidemiological aspects. Ann Neurol. 1984;15:335-341.
109. Amaducci LA, Fratiglioni L, Rocca WA, et al. Risk factors for clinically diagnosed Alzheimer's disease: a case-control study of an Italian population. Neurology. 1986;36:922-931.
110. Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer's disease in Australia. Neurology. 1990;40:1698-1707.
111. Graves AB, White E, Koepsell TD, et al. A case-control study of Alzheimer's disease. Ann NeuroL 1990;28:766-774.
112. Brenner DE, Kukull WA, Stergachis A, et al. Post-menopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol. 1994; 140:262-267.
113. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol. 1994;51: 896-900.
114. Mortel KF, Meyer JS. Lack of postmenopausal estrogen replacement therapy and the risk of dementia. J Neuropsychiatry Clin Neurosci. 1995; 7:334-337.
115. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology. 1997;48:1517-1521.
116. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998;279:688-695.
117. Costa MM, Reus VI, Wolkowitz OM, Manfredi F, Lieberman M. Estrogen replacement therapy and cognitive decline in memory-impaired postmenopausal women. Biol Psychiatry. 1999;46: 182-188.
118. Doraiswamy PM, Bieber F, Kaiser L, Krishnan KR, Reuning-Scherer J, Gulanski B. The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology. 1997;48:1511-1517.
119. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology. 1996;46:1580-1584.
120. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology. 2000;54:295-301.
121. Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study, Neurology. 2000; 54:2061-2066.
122. Gibbs RB. Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats. Neurobiol Aging. 2000;21:107-116.
123. Lindsay R. The menopause: sex steroids and osteoporosis. Clin Obstet Gynecol. 1987;30:847-859.
124. Shumaker SA, Reboussin BA, Espeland MA, et al. The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials. 1998;19:604-621.
125. Wren BG. Megatrials of hormonal replacement therapy. Drugs Aging. 1998;12:343-348.